An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD
Clinical trial NCT01985126 · COMPLETED
Trial details
- NCT number
- NCT01985126
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-09-27
- Primary completion
- 2015-01-09
- Enrollment
- 124
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.